Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Why 93% Of Aerovate Therapeutics' Value Just Went Up In Smoke
In This Article:
Aerovate Therapeutics said Monday its experimental blood pressure medicine failed in Phase 2 testing, and the biotech stock plummeted 93%.
Terms and Privacy Policy